BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu D. Isocitrate dehydrogenase 2 inhibits gastric cancer cell invasion via matrix metalloproteinase 7. Tumour Biol 2016;37:5225-30. [PMID: 26553362 DOI: 10.1007/s13277-015-4358-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Qiao S, Lu W, Glorieux C, Li J, Zeng P, Meng N, Zhang H, Wen S, Huang P. Wild-type IDH2 protects nuclear DNA from oxidative damage and is a potential therapeutic target in colorectal cancer. Oncogene 2021. [PMID: 34349242 DOI: 10.1038/s41388-021-01968-2] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
2 Ju HQ, Lin JF, Tian T, Xie D, Xu RH. NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications. Signal Transduct Target Ther 2020;5:231. [PMID: 33028807 DOI: 10.1038/s41392-020-00326-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 64] [Article Influence: 9.5] [Reference Citation Analysis]
3 Baj J, Korona-Głowniak I, Forma A, Maani A, Sitarz E, Rahnama-Hezavah M, Radzikowska E, Portincasa P. Mechanisms of the Epithelial-Mesenchymal Transition and Tumor Microenvironment in Helicobacter pylori-Induced Gastric Cancer. Cells 2020;9:E1055. [PMID: 32340207 DOI: 10.3390/cells9041055] [Cited by in Crossref: 18] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
4 Wang Y, Agarwal E, Bertolini I, Ghosh JC, Seo JH, Altieri DC. IDH2 reprograms mitochondrial dynamics in cancer through a HIF-1α-regulated pseudohypoxic state. FASEB J 2019;33:13398-411. [PMID: 31530011 DOI: 10.1096/fj.201901366R] [Cited by in Crossref: 8] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
5 Zhang J, Hu L, Wang H, Zhi J, Hou X, Wu Y, Zheng X, Gao M. Functional analysis and clinical significance of the isocitrate dehydrogenase 2 gene in papillary thyroid carcinoma. Cancer Manag Res 2019;11:3765-77. [PMID: 31118795 DOI: 10.2147/CMAR.S194920] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
6 Bergaggio E, Piva R. Wild-Type IDH Enzymes as Actionable Targets for Cancer Therapy. Cancers (Basel) 2019;11:E563. [PMID: 31010244 DOI: 10.3390/cancers11040563] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
7 Bergaggio E, Riganti C, Garaffo G, Vitale N, Mereu E, Bandini C, Pellegrino E, Pullano V, Omedè P, Todoerti K, Cascione L, Audrito V, Riccio A, Rossi A, Bertoni F, Deaglio S, Neri A, Palumbo A, Piva R. IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies. Blood 2019;133:156-67. [PMID: 30455381 DOI: 10.1182/blood-2018-05-850826] [Cited by in Crossref: 17] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
8 Wang X, Zhi Q, Liu S, Xue SL, Shen C, Li Y, Wu C, Tang Z, Chen W, Song JL, Bao M, Song YH, Zhou J. Identification of specific biomarkers for gastric adenocarcinoma by ITRAQ proteomic approach. Sci Rep 2016;6:38871. [PMID: 27941907 DOI: 10.1038/srep38871] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]